Aidoc launches seven new AI solutions to tackle Europe's healthcare challenges
Press releases may be edited for formatting or style | September 03, 2024
Artificial Intelligence
LONDON, Sept. 3, 2024 /PRNewswire/ -- Today, Aidoc, a leading healthcare AI provider, introduced seven new AI solutions to the European healthcare market. These additions mark a significant expansion of Aidoc's award-winning aiOS™ platform, which alerts radiologists and care teams to suspected urgent pathologies in medical images, ensuring rapid delivery of treatment to patients.
The new algorithms, which have now all achieved medical device CE-marking under MDR, include four solutions for notifying and triaging urgent pathologies: vessel occlusion, aortic dissection, vertebral compression fractures and malpositioned endotracheal tube. Alongside these, there are three new quantification solutions that provide standardised quantitative assessments of cardiovascular and neurological conditions: midline shift, coronary artery calcification and abdominal aortic measurement.
With this latest release, Aidoc's aiOS™ platform now offers 26 AI solutions approved for the European market, including 17 homegrown algorithms and others developed through strategic partnerships. This comprehensive suite of CE-marked clinical AI solutions is deployed via the Aidoc aiOS™ platform, delivering a seamless and unified user experience. Together with Aidoc's care coordination and patient follow-up features, this solidifies Aidoc as the leading provider of end-to-end AI solutions for healthcare.
"Health systems in Europe face severe challenges with increasing patient backlogs and staff shortages. To address these challenges, we are now taking clinical AI to the next level by increasing the speed and the scope of developing and implementing new AI-modules" said Alexander Boehmcker, VP Europe at Aidoc. "Aidoc has already established itself as the leading clinical AI platform. With the introduction of these new solutions, we have scaled up our capability to flag more pathologies, and provide important measurements with our new quantification solutions. Coupled with our platform's ability to rapidly activate care teams and ensure robust patient follow-up, we're poised to deliver better outcomes for patients and providers. I am especially proud that now all our Aidoc AI-modules are CE-marked under the new MDR".
Aidoc's AI platform, which is extensively deployed across Europe is already backed by substantial evidence demonstrating its effectiveness at tackling Europe's healthcare challenges. Namely, a recent study using Aidoc's AI at the Netherlands Cancer Institute reported a 98% reduction in patient wait times for notification of incidental pulmonary embolism, a common co-morbidity on Oncology patients (1).
|
|
You Must Be Logged In To Post A Comment
|